Regulatory round-up: 17 November 2025

The past week has brought a steady flow of signals from major global regulators, offering a snapshot of how oversight is shifting as the year closes. In the United States, the Food and Drug Administration has advanced policy measures that point toward a more adaptable, data-focused approach to medicine evaluation, particularly in settings where traditional trials are difficult to execute.

Across Europe, the European Medicines Agency and its Committee for Medicinal Products for Human Use continue to release scientific opinions and meeting outcomes that help shape expectations for upcoming authorisations. Even when actions stop short of formal approvals, the pattern of recommendations provides useful direction for companies mapping out regulatory plans.

Elsewhere, national agencies are refining their frameworks in response to supply pressures, new technologies and evolving therapeutic trends.